Skip to main content
Equibles
VERA logo

VERA · Vera Therapeutics, Inc.

Track VERA — free

Use VERA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VERA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$29.38 -1.04 (-3.42%)
Russell 2000 member Rebalance outlook locked
Market Cap
$2.34B
Shares
72.06M
Volume · Oct 5 955.61K Avg daily vol (3M) 2.28M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$30.42 Open$31.16 Day$29.80–31.27 52W close$24.10–55.67 Avg vol 30d2.3M Short int17.0M · 23.6% float · 6.2d Short vol54% Last earningsNov 5, 2025 DataMay 2021–Oct 2026 Filing10-Q · Aug 10

Up next

Latest filing: 10-Q
filed Aug 10, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$401.89M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-14.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$423.93M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+12.6%
Year over year · more shares
Price change (1Y)
+4.2%
Trailing year
Short interest
23.6%
Latest settlement · 6.2 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −22%
below
Price vs 50-day avg −8%
below
RSI (14) 38
neutral
MACD trend Negative
52-week position 20%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −13%
trailing
6-month return −30%
trailing
YTD return −40%
this year
Relative strength −43%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $33 › 200d $39 — 200d above 50d
Institutional flow Distributing
1 of 222 funds reported for Sep 30 · net -3 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
23.64% of float · ▼ -14.3% MoM · 6.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
222 holders — mid 3-yr range
Squeeze score 61
elevated · 0–100
Fundamentals
Weak
EPS growth −69%
Y/Y
Free cash flow $-241.7M
Balance sheet $279.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 61%
annualized · 1-yr
Max drawdown −48%
past year
ATR 6.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−22% Bearish
Price vs 50-day avg
−8% Bearish
RSI (14)
38 Neutral
MACD trend
Negative Bearish
52-week position
20% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $33 › 200d $39 — 200d above 50d
Institutional flow Distributing
1 of 222 funds reported for Sep 30 · net -3 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
23.64% of float · ▼ -14.3% MoM · 6.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
222 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $24 Now $30 · 20% Range high $56
vs 200-day avg -22% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VERA
Vera Therapeutics, Inc.
this stock
$2.34B -39.9% — — 23.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
222
% held
108.8%
Reported
1 of 222
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
204
View
Short & Settlement
Short Interest Falling
Shares short
17.0M
Days to cover
6.2d
Change
-2.8M sh
View
Short Volume
Short vol %
54%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
14
Value
$491
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
60.5%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-299.6M
EPS diluted
$-4.66
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 15, 2026
This year
14
View
Proposed Sales
Value
$2.2M
Shares
64.8K
Filed
Sep 2, 2026
View
Exempt Offerings
Offering
$70.7M
Filed
Feb 25, 2021
View
Earnings & Events
Webcasts
Last webcast
Sep 15, 2026
View
Investor Relations
Latest news
Vera Therapeutics Announces Induc…
Published
Oct 2, 2026
View

Performance

5D 20D 120D MTD YTD
VERA -6.5% -13.1% -30.4% -5.8% -39.9%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -6.3% -12.6% -42.6% -6.7% -52.8%
Key facts CIK 1831828 CUSIP 92337R101 13F (30d) 4 filings 4 filers Visit website Investor relations